Biotek-snakken — Oktober 2019
-
-
Zymeworks also has ambitious plans in GEA, where it will need its efficacy results to rise to the challenge; with partner BeiGene, the company is planning a registrational trial in GEA to treat HER2-positive patients in the first line setting, running a head-to-head comparison against Herceptin.
-
Antistoffer med dobbelt virkning https://www.proinvestor.com/index.php?p=debat_1&postid=78487
-
-
-
Fremragende Sukkeralf.

-
@sukkeralf, tak for flot arbejde, er med fra ca 14 USD, og kan ikke tåle tanken om skat, så lader det hele løbe indtil vi får nyheder på zw49.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind